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ABSTRACT 
The mechanisms of cellular and humoral immune responses against P. vivax parasite remain poorly understood. 
Several malaria immunological studies have been conducted in endemic regions where both P. falciparum and P. 
vivax parasites co-exist. In this study, a comparative analysis of immunity to Plasmodium vivax antigens in dif-
ferent geography and incidence of Plasmodium spp. infection was performed. We characterised antibodies 
against two P. vivax antigens, PvMSP-1 and PvAMA-1, and the cross-reactivity between these antigens using 
plasma from acute malaria infected patients living in the central region of China and in the western border of 
Thailand. P. vivax endemicity is found in central China whereas both P. vivax and P. falciparum are endemic in 
Thailand. There was an increased level of anti-PvMSP-1/anti-PvAMA-1 in both populations. An elevated level 
of antibodies to total P. vivax proteins and low level of antibodies to total P. falciparum proteins was found in 
acute P. vivax infected Chinese, suggesting antibody cross-reactivity between the two species. P. vivax infected 
Thai patients had both anti-P. vivax and anti-P. falciparum antibodies as expected since both species are present 
in Thailand. More information on humoral and cell mediated immunity during acute P. vivax-infection in the ar-
ea where only single P. vivax species existed is of great interest in the relation of building up anti-disease severi-
ty caused by P. falciparum. This knowledge will support vaccine development in the future. 
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INTRODUCTION 
Malaria remains one of the most devas-
tating infectious diseases due to its influence 
on more than 225 million individuals and 
approximately 700 thousand deaths each 
year. The majority of malaria infections are 
caused by Plasmodium falciparum in Afri-
can countries (Sachs and Malaney, 2002). 
However, as the most widely distributed 
human malaria parasite, Plasmodium vivax 
can also cause life-threatening symptoms 
even though it was previously considered 
benign. In contrast to P. falciparum, studies 
on P. vivax have lagged behind, largely due 
to the fact that this parasite cannot be cul-
tured continuously in vitro. The mechanisms 
of cellular and humoral immune responses 
against P. vivax parasite also remain poorly 
understood. Other reasons for the neglect of 
“benign” P. vivax malaria could be the diffi-
culty in accessing P. vivax-infected cases. 
Several studies have been conducted in en-
demic regions where both parasites co-exist 
(Snounou and White, 2004; Rodrigues et al., 
2005; Oliveira et al., 2006; Wickramarachchi 
et al., 2007; Michon et al., 2007; 
Chuangchaiya et al., 2010; Kochar et al., 
2010; Lin et al., 2010; Douglas et al., 2011; 
Lin et al., 2011). The strain-specific and se-
rological cross-reactive immunity between 
P. falciparum and P. vivax blood stage anti-
gens has been documented (Diggs and 
Sadun, 1965, Woodberry et al., 2008, Doo-
lan et al., 2009). However, very few studies 
were conducted in areas where only P. vivax 
causes infection (Jangpatarapongsa et al., 
2012). Therefore, a comparative study of 
immunity to P. vivax antigens in different 
endemic settings will contribute to a better 
understanding on the development and dy-
namics of host immunity to P. vivax infec-
tions.  
Strong humoral immune responses to 
Plasmodium can be induced in residents of 
malaria endemic areas (Wipasa et al., 2002) 
The level of total antimalarial antibodies in-
creases with age and depends on the length 
and intensity of exposure to malaria. Anti-
body-mediated inhibition of parasites is 
more efficient in blood stage than in liver 
stage infections (Troye-Blomberg and Perl-
mann, 1988). Antibodies also mediate anti-
body-dependent cellular cytotoxicity and 
phagocytosis involving polymorphonuclear 
cells, neutrophils or platelets (Bolad and 
Berzins, 2000).  
To understand the natural immune re-
sponse during P. vivax infection in central 
China where only P. vivax is present and 
western Thailand with P. vivax and P. falci-
parum were almost equally prevalent (WHO, 
2013), we determined antibodies in the pa-
tients’ sera against proteins extracted from P. 
vivax parasites and recombinant proteins 
PvMSP1(19) and PvAMA-1 produced in 
Escherichia coli (Soares et al., 1997; 1999a, 
b; Rodrigues et al., 2003). Our study aimed 
to characterize the level of IgG antibodies 
following P. vivax infection comparing two 
malaria endemic areas having different geog-
raphy and incidence of Plasmodium spp. in-
fection. 
 
MATERIALS AND METHODS 
Study population 
Plasma samples were collected from 76 
patients with acute P. vivax infections (AC) 
at Wuhe County Hospital, Guzhen County 
Hospital, The First City Hospital, Bengbu 
city, Anhui Province, China. The patients 
were enrolled sequentially during June and 
July of 2009 and 2010. All patients enrolled 
in this study are inhabitants of Wuhe County, 
Guzhen County or the Bengbu City suburbs. 
Malaria transmission in this region is non-
stable but can lead to malaria endemic in 
China. In the 1960s and 1970s, there were 
two malaria epidemics which were primarily 
caused by the P. vivax parasite. P. falcipa-
rum and P. vivax parasites were found to-
gether in this region until the end of the 
1980s, but P. falciparum has not been found 
since the early 1990s. During the first decade 
of this century (from 2000 to 2010), malaria 
in this and other regions of China was main-
ly caused by the P. vivax parasite.  
In Thailand plasma samples were col-
lected from 52 patients from malaria clinics 
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at Mae Sot and Mae Kasa, Tak Province, 
who were enrolled sequentially during 2009 
and 2010. The diagnosis of P. vivax malaria 
infection was based on the examination of 
Giemsa-stained thick and thin blood films. 
Polymerase chain reaction (PCR) with spe-
cies-specific primers was performed on 
DNA isolated from the blood samples to fur-
ther verify P. vivax infections (Snounou et 
al., 1993).  
Blood samples were collected from 32 
Chinese and 53 Thai people who did not suf-
fer from P. vivax at the time of blood collec-
tion determined by both microscopy and 
PCR residing in the same P. vivax-endemic 
area as “immune controls” (IC). Another 20 
healthy Chinese adults living in Wuxi city, 
China and 27 healthy Thai adults living in 
Bangkok, Thailand without previous malaria 
exposure were recruited to serve as “naïve 
controls” (NC). The clinical characteristics 
of the subjects are listed in Table 1. This 
study was approved by Ethical Approval 
Committee of Biomedical Institute of Anhui 
Medical University and Committee on Hu-
man Rights Related to Human Experimenta-
tion, Mahidol University. Informed consents 
were obtained from each individual before a 
blood sample was taken. 
 
Parasite culture and antigen preparation 
P. vivax-infected red blood cells (iRBC) 
purified from infected blood were used as 
crude antigens for coating. Briefly, P. vivax 
infected bloods were depleted of white blood 
cells by filtering through a sterile column of 
CF11 cellulose (Whatman®, Maidstone, UK) 
and the red blood cells were washed with 
RPMI-1640 by centrifugation at 1190 g for 
5 minutes. The parasites were cultured for 24 
– 30 hours at 5 % hematocrit in McCoy’s 5A 
medium (GIBCO, Carlsbad, USA) supple-
mented with 25 % human AB serum. P. vi-
vax parasites were maintained in an incuba-
tor containing 5 % CO2, 5 % O2 and 90 % N2 
until matured to schizont stage ( 6 nuclei). 
P. faciparum culture was performed as de-
scribed previously (Jangpatarapongsa et al., 
2006). The late stage iRBC were enriched by 
centrifugation using 60 % Percoll (GE 
Healthcare, Uppsala, Sweden) at 1190 g for 
10 minutes. The enriched iRBC pellets were 
sonicated for 40 seconds at 150 watts and the 
protein concentration was determined by 
Bradford assay (Bio-Rad, Hercules, USA). 
The proteins were then aliquoted and stored 
at -70 °C until use. Uninfected RBCs were 
processed similarly as above and equivalent 
amount of protein concentration to the ma-
laria antigens was stored at -70 °C to be used 
as a negative control. 
 
Protein expression and purification 
A blood filter paper from P. vivax-
infected patients from Thailand was used to 
extract genomic DNA. PCR was used to ob-
tain the MSP-1(19) fragment by using pri-
mers in Table 2. Sequences were cut with 
BamH I and Xho I and cloned into pET28a 
vector. Protein was expressed in E. coli 
BL21. IPTG was used for protein induction 
and cell pellet was collected and sonicated. 
Protein was purified by using native condi-
tion as described by manufacturer’s protocol 
(Qiagen, USA). Supernatant was collected 
and protein was purified by Ni-NTA beads. 
Finally, eluted protein was checked for ex-
pression by SDS-PAGE and kept at -20 °C.  
For PvAMA-1, PCR was performed to 
amplify PvAMA-1 gene from a Thai P. vivax 
sample by using the designed primers in Ta-
ble 2. Sequences were cut using Nde I and 
Xho I and cloned into pET22b vector. Pro-
tein was expressed in E. coli BL21, purified 
and checked for expression in similar pro-
cesses to PvMSP-1(19) as mentioned above.  
 
ELISA analysis and IgG antibody level in 
plasma 
There were three groups of plasma sam-
ples analyzed: AC group (n = 76), IC group 
(n = 32), and NC group (n = 20). There were 
five soluble antigens used: NRBC (10 μg/ 
ml), PV (10 μg/ml), PF (10 μg/ml), PvMSP-
1 (0.25 μg/ml), and PvAMA-1 (0.1 μg/ml). 
50 μl of antigens were pipetted to each ELI-
SA well and plates were stored in wetted box 
at 4 °C overnight. Then the plates were
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Table 1: Information and clinical data of P.vivax patients, immune and naïve controls 
 No. 
Sex 
Age Temperature (oC) 
Parasitemia 
( %) M F 
Chinese 
Naïve controls 20 7 13 25 ± 7 36.8 ± 0.2 0 
Immune controls 32 19 13 33 ± 11 36.5 ± 0.5 0 
Acute P. vivax 76 34 42 36 ± 10 37.9 ± 0.9 0.5 ± 0.2 
Thai 
Naïve controls 27 15 12 32 ± 12 37.5 ± 0.5 0 
Immune controls 53 40 13 40 ± 15 36.8 ± 0.4 0 
Acute P. vivax 52 32 20 32 ± 12 37.8 ± 1.3 0.4 ± 0.4 
 
Table 2: PCR primers and sequences 
Name Sequences 5’ 3’ (enzymes)(vectors) 
PvMSP1(19) Forward 
PvMSP1(19) Reverse 
CG GGATCC aat gtg caa act cag tta tta ac (BamHI) (PET28a) 
CCG CTC GAG gct gga gga gct aca gaa aac (Xho I) 
PvAMA Forward 
PvAMA Reverse 
GGAATTC CAT ATG acc gtt gag aga agc aca cg (Nde I) (PET22b) 
CCG CTC GAG tag tag cat ctg ctt gtt cg (XhoI) 
 
washed and blocked with 5 % skimmed milk 
for 2 h at 37 °C. Plasma samples were dilut-
ed (1: 100) and added to each well (50 μl). 
The plates were enclosed in wetted box and 
incubated for 2 h at 37 °C. After washing 3 
times using TBS-T, 50 μl of HRP-conjugated 
goat anti human IgG (H&L chain) antibody 
was added into each well, then plates were 
enclosed in wetted box again, and incubated 
for another 2 h at 37 °C. TBS-T was used to 
wash the plate then 50 μl of ABST substrate 
were added to each well. The plate was 
stored in the dark for 1 h at room tempera-
ture. All absorption was determined at A405 
and the final OD values of PV and PF anti-
gen were obtained by subtracting the OD 
values from NRBC group. 
 
RESULTS  
A comparison of anti-P. vivax antibody  
after being intected with P. vivax parasite 
between Thai and Chinese patients 
Anti-crude PV 
There was significant difference of base 
line antibody level among naïve controls 
against P. vivax-extracted antigens between 
Chinese (OD = 0.07) and Thai (OD = 0.03) 
(MD = 0.07, 95 % CI = 0.04-0.1, P < 0.001) 
(Figure 1A). After infection by P. vivax, sig-
nificant elevation of antibodies were found 
in both patient groups Chinese (0.85) and 
Thai (0.14). However, the level of antibody 
in P. vivax infected Chinese patients was 
higher than that of the Thai patients. Similar 
to naïve controls, the immune Chinese con-
trols (0.8) had higher levels of antibodies 
against the P. vivax antigens than that of the 
Thai controls (0.07). 
Anti-P. vivax MSP-1 (19)  
Baseline values of mean level of antibod-
ies to PvMSP-1(19) among healthy Thai 
controls and Chinese population living out-
side (naïve controls) and inside (immune 
controls) endemic areas were compared 
(Figure 1B). We found that the mean level of 
total antibodies in Thai naïve controls (OD = 
0.3) was higher than that of Chinese naïve 
controls (OD = 0.03) (P < 0.001). Moreover, 
the level of antibodies in people living in P. 
vivax endemic area was significantly differ-
ent between Thai (0.31) and Chinese popula-
tions (0.06) (P < 0.001). Two samples of 
Thai healthy controls had antibodies to 
PvMSP-1(19) as high as P. vivax infected 
patients as shown in above figure, and
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Figure 1: Absorbance (405 nm) value of IgG antibody reacting with (A) crude P. vivax antigens, (B) 
recombinant P. vivax MSP-119 protein, (C) recombinant P. vivax AMA-1 protein, and (D) crude P. fal-
ciparum antigen respectively, in the naïve controls (NC), immune controls (IC), acute P. vivax infection 
(AC) comparing between Chinese and Thai patients. Data are shown in median, interquartile ranges 
(box plots), maximum and minimum (upper-lower lines). 
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were excluded from the baseline value. 
Among both population groups, the mean 
level of total antibodies to PvMSP-1(19) was 
significantly increased during acute P. vivax 
infection in both Thai (0.8) (P < 0.001) and 
Chinese (0.5) (P < 0.001) patients. Interest-
ingly, the significantly higher levels of anti-
bodies among P. vivax infected Thai com-
pared to Chinese patients (P = 0.02) were 
observed.  
Anti-P. vivax AMA-1 
The mean level of antibodies against 
PvAMA-1 among healthy controls living 
outside the P. vivax endemic area was very 
low both in Thai (OD = 0.1) and in Chinese 
populations (OD = 0.03) (Figure 1C). How-
ever, the level was significantly higher 
among the Thai population compared to the 
Chinese population (P < 0.000). There was a 
higher level among Thai (0.2) than Chinese 
immune controls (0.1) (P < 0.001). There 
was no significant difference in the level of 
antibodies against PvAMA-1 in the healthy 
Thai donors living inside and outside endem-
ic areas (P > 0.05) in contrast to that found in 
the Chinese donors (P < 0.001). In acute P. 
vivax infection, the level was significantly 
higher compared to naïve controls (Thai 
P =< 0.001, Chinese P < 0.0.001). However, 
among P. vivax patients, we did not find sig-
nificant difference between Thai (0.3) and 
Chinese (0.2) populations (P > 0.05). We al-
so found a sample of P. vivax infected pa-
tient that had obviously high level of anti-
bodies to PvAMA-1, so this was excluded 
from the baseline value.  
Cross reactivity between P. vivax and P. fal-
ciparum antigens 
To examine the immune cross-reactivity 
between P. vivax and P. falciparum antigens, 
the P. vivax and P. falciparum extracted an-
tigens were used as coated antigens on the 
ELISA plates. The median percentage of 
baseline level antibodies in naïve controls 
among Chinese was very low (OD = 0.003) 
and was significantly lower than that of Thai 
(OD = 0.04) donors (MD = 0.07, 95 % 
CI = 0.04-0.1, P < 0.001) (Figure 1D). 
Moreover, significantly higher levels of anti-
bodies against P. falciparum antigens were 
observed in immune controls between Thai 
(0.18) and Chinese (0.01) (MD = 0.6, 
95 %CI = 0.45-0.75). After infection with P. 
vivax, patients had higher levels of antibod-
ies against P. falciparum in Thai patients 
(OD = 0.36) than in Chinese patients 
(OD = 0.07). 
 
DISCUSSION 
In this study, we provide evidence that 
Thai villagers having had P. vivax infection 
and living in the endemic area did not pro-
duce high level of anti-P. vivax-specific anti-
bodies (Jangpatarapongsa et al., 2006) as 
tested with total proteins extracted from the 
parasites. We confirmed the presence of an-
tibodies to P. vivax antigens by testing with 
recombinant P. vivax proteins, i.e. 
PvMSP1(19) and PvAMA1, then compared 
the level of natural antibodies between two 
P. vivax endemic areas in China and in Thai-
land. The species specific antibodies could 
tell us the cross-reactivity between P. falci-
parum and P. vivax which led to the exami-
nation of epidemiological status in those are-
as.  
Previously, a passive transfer of immune 
IgG to Gambian children was shown to pro-
vide protection (McGregor, 1964). The im-
munity against blood stage of P. falciparum 
infection is associated with class and sub-
class of IgG antibody (Shi et al., 1999). Sim-
ilarly, IgG1 and IgG3 are predominant 
among P. vivax-infected patients with history 
of malaria (Pinto et al., 2001). Recent study 
has shown anti-P. vivax merozoite surface 
protein 1 (MSP-1) IgG among subjects with 
distinct degrees of malaria exposure in en-
demic area. The IgG1 and IgG3 against P. 
vivax are higher among the subjects with one 
year-exposure period than the group with 
longer years of exposure (Morais et al., 
2005). PvMSP-1(19) is shown to induce 
immunity in non-human primates (Rosa et 
al., 2006).  
Our study showed no significant differ-
ence of base line level anti-P. vivax antibod-
EXCLI Journal 2015;14:926-934 – ISSN 1611-2156 
Received: June 05, 2015, accepted: July 13, 2015, published: August 06, 2015 
 
 
932 
ies among Chinese and Thai patients. We 
found higher levels of anti-P. vivax antibod-
ies in Chinese than in Thai immune controls. 
Moreover, this level was very high in simi-
larity to that shown in the acute P. vivax in-
fection. This could be that P. vivax endemici-
ty in China was greater than in Thailand, alt-
hough the two areas in both countries are 
hypo-endemic.  
However, in contrast to what we found in 
anti- P. vivax antibodies, the base line level 
of anti-MSP-1 and anti-AMA-1 antibodies 
was significantly lower in naïve Chinese 
controls than in naïve Thai controls. A pos-
sible reason could be that some of these ma-
laria naïve Thai donors might have had ma-
laria experiences but were asymptomatic 
and, therefore, there were lower levels of an-
tibodies that persisted in their circulation.  
In our study, we found the level of anti-
MSP-1 antibodies was significantly lower in 
immune controls and acute P. vivax infected 
Chinese. A possible reason is that the re-
combinant protein rMSP-1(19) was obtained 
from the P. vivax parasites infecting Thai pa-
tients. There may be difference in the gene 
sequence of P. vivax MSP-1(19) between 
those from Thailand and those from China 
(Birkenmeyer et al., 2010). 
Crude P. falciparum antigen was used in 
this study to determine the species specific 
antibody and the cross-reactivity. We found 
very low levels of base line anti-P. falcipa-
rum antibodies among naïve controls and 
immune controls of Chinese donors. After 
infection with P. vivax, Chinese patients had 
somewhat higher levels of anti-P. falciparum 
antibodies. These results were in contrast to 
those found in Thailand. Higher levels of 
base line anti-P. falciparum antibody was 
found among naïve and immune Thai con-
trols. Moreover, development of anti-P. fal-
ciparum antibodies in P. vivax infected pa-
tients in Thailand were much higher than 
that in China. Taken together, this suggests 
that a cross-reactivity among epitopes/anti-
gens between the two malaria species do ex-
ist. However, it does not over rule the fact 
that the anti-P.falciparum antibody may be 
maintained in the P. vivax-infected Thai pa-
tients since both parasites are common in the 
area. Our findings led to the hypothesis that 
a protection against severe malaria caused by 
P. falciparum might be obtained via vaccina-
tion with a common antigen(s) of a benign 
malaria parasite such as P. vivax.  
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